121 related articles for article (PubMed ID: 18378560)
1. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial.
Qorbani M; Sanginabadi M; Mohajeri-Tehrani MR; Karimi S; Gerami H; Mahdavi-Gorabi A; Shirzad N; Samadi M; Baygi F; Hosseini S; Mansour A
Front Endocrinol (Lausanne); 2020; 11():590392. PubMed ID: 33408691
[TBL] [Abstract][Full Text] [Related]
3. Is interleukin-18 associated with polycystic ovary syndrome?
Yang Y; Qiao J; Li R; Li MZ
Reprod Biol Endocrinol; 2011 Jan; 9():7. PubMed ID: 21244650
[TBL] [Abstract][Full Text] [Related]
4. Obesity contributes to telomere shortening in polycystic ovary syndrome.
Kogure GS; Verruma CG; Santana BA; Calado RT; Ferriani RA; Furtado CLM; Dos Reis RM
Reprod Sci; 2024 Jun; 31(6):1601-1609. PubMed ID: 38393627
[TBL] [Abstract][Full Text] [Related]
5. Body mass index is a good predictor of metabolic abnormalities in polycystic ovary syndrome.
Fruzzetti F; Fidecicchi T; Benelli E; Baldari F; Tonacchera M
J Endocrinol Invest; 2024 Apr; 47(4):927-936. PubMed ID: 37907709
[TBL] [Abstract][Full Text] [Related]
6. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome.
Ebrahimi-Mamaghani M; Saghafi-Asl M; Pirouzpanah S; Aliasgharzadeh A; Aliashrafi S; Rezayi N; Mehrzad-Sadaghiani M
J Health Popul Nutr; 2015 Mar; 33(1):157-67. PubMed ID: 25995732
[TBL] [Abstract][Full Text] [Related]
7. Relationship of obesity-related disturbances with LH/FSH ratio among post-menopausal women in the United States.
Beydoun HA; Beydoun MA; Wiggins N; Stadtmauer L
Maturitas; 2012 Jan; 71(1):55-61. PubMed ID: 22088801
[TBL] [Abstract][Full Text] [Related]
8. Association of Macronutrients Composition, Physical Activity and Serum Androgen Concentration in Young Women with Polycystic Ovary Syndrome.
Mizgier M; Watrowski R; Opydo-Szymaczek J; Jodłowska-Siewert E; Lombardi G; Kędzia W; Jarząbek-Bielecka G
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010948
[TBL] [Abstract][Full Text] [Related]
9. Determinants of Bone Mineral Density in Iranian Women with Polycystic Ovary Syndrome.
Karimi F; Mardani P
Int J Endocrinol Metab; 2023 Oct; 21(4):e137594. PubMed ID: 38666045
[TBL] [Abstract][Full Text] [Related]
10. Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism.
Suresh S; Vijayakumar T
Indian J Clin Biochem; 2015 Jul; 30(3):345-50. PubMed ID: 26089623
[TBL] [Abstract][Full Text] [Related]
11. Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients.
Ma Q; He X; Fu Z; Ren X; Sun R; Zhu S; Bian Y; Li X
J Med Biochem; 2024 Apr; 43(2):226-233. PubMed ID: 38699692
[TBL] [Abstract][Full Text] [Related]
12. Clustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome.
van der Ham K; Moolhuijsen LME; Brewer K; Sisk R; Dunaif A; Laven JSE; Louwers YV; Visser JA
J Clin Endocrinol Metab; 2024 May; ():. PubMed ID: 38753423
[TBL] [Abstract][Full Text] [Related]
13. Increased GPC4 and clusterin associated with insulin resistance in patients with PCOS.
Chen Z; Zeng H; Huang Q; Lin C; Li X; Sun S; Liu JP
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38251963
[TBL] [Abstract][Full Text] [Related]
14. Outdoor artificial light at night and reproductive endocrine and glucose homeostasis and polycystic ovary syndrome in women of reproductive age.
Fang L; Ma C; Wang G; Peng Y; Zhao H; Chen Y; Ma Y; Cai G; Cao Y; Pan F
Epidemiology; 2024 Mar; ():. PubMed ID: 38534181
[TBL] [Abstract][Full Text] [Related]
15. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial.
Ismail AM; Hamed AH; Saso S; Thabet HH
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():148-52. PubMed ID: 25015747
[TBL] [Abstract][Full Text] [Related]
16. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Samimi M; Jamilian M; Ebrahimi FA; Rahimi M; Tajbakhsh B; Asemi Z
Clin Endocrinol (Oxf); 2016 Jun; 84(6):851-7. PubMed ID: 26666519
[TBL] [Abstract][Full Text] [Related]
17. Plasma L-carnitine levels of obese and non-obese polycystic ovary syndrome patients.
Celik F; Kose M; Yilmazer M; Köken GN; Arioz DT; Kanat Pektas M
J Obstet Gynaecol; 2017 May; 37(4):476-479. PubMed ID: 28141959
[TBL] [Abstract][Full Text] [Related]
18. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Jamilian H; Jamilian M; Samimi M; Afshar Ebrahimi F; Rahimi M; Bahmani F; Aghababayan S; Kouhi M; Shahabbaspour S; Asemi Z
Gynecol Endocrinol; 2017 Jun; 33(6):442-447. PubMed ID: 28277138
[TBL] [Abstract][Full Text] [Related]
19. Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Jamilian M; Asemi Z
Ann Nutr Metab; 2015; 67(1):42-8. PubMed ID: 26279073
[TBL] [Abstract][Full Text] [Related]
20. [The biological function of L-carnitine and its content in the particular food examples].
Rospond B; Chłopicka J
Przegl Lek; 2013; 70(2):85-91. PubMed ID: 23879010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
